Showing posts with label HPV. Show all posts
Showing posts with label HPV. Show all posts
Friday, 17 December 2010
CDC Issues Updated STD Treatment Guidelines
The Centers for Disease Control and Prevention (CDC) issued updated Sexually Transmitted Diseases Treatment Guidelines—2010. The guidelines appear in the December 17, 2010 issue of Morbidity and Mortality Weekly Report (MMWR) Recommendations and Reports.
The Guidelines, which were previously issued in 2006, are based on newly available evidence and serve as a source of clinical guidance and advise health care providers on the most effective treatment regimens, screening procedures, and prevention and vaccination strategies for STDs. The new guidelines include expanded STD prevention recommendations, including HPV vaccination; revised guidance on the diagnostic evaluation and management of syphilis; revised gonorrhea treatment regimens; and other topics.
Over 19 million cases of STDs occur in the United States each year, with a disproportionate share among young people and racial and ethnic minority populations. The estimated annual direct medical costs of treating STDs and their sequelae are $16.4 billion. Left untreated, STDs can cause serious health problems ranging from infertility to increased risk of HIV infection. Partnership for Prevention is working through the National Chlamydia Coalition (NCC) to address the continued high burden of chlamydia infection, especially among women age 25 and under. For more information on the NCC, visit www.prevent.org/ncc.
The Guidelines are available at www.cdc.gov/std/treatment/2010/. For more information, contact 800-CDC-INFO (800-232-4636) or e-mail cdcinfo@cdc.gov.
Susan K. Maloney, MHS
Managing Senior Fellow and Senior Program Officer
The Guidelines, which were previously issued in 2006, are based on newly available evidence and serve as a source of clinical guidance and advise health care providers on the most effective treatment regimens, screening procedures, and prevention and vaccination strategies for STDs. The new guidelines include expanded STD prevention recommendations, including HPV vaccination; revised guidance on the diagnostic evaluation and management of syphilis; revised gonorrhea treatment regimens; and other topics.
Over 19 million cases of STDs occur in the United States each year, with a disproportionate share among young people and racial and ethnic minority populations. The estimated annual direct medical costs of treating STDs and their sequelae are $16.4 billion. Left untreated, STDs can cause serious health problems ranging from infertility to increased risk of HIV infection. Partnership for Prevention is working through the National Chlamydia Coalition (NCC) to address the continued high burden of chlamydia infection, especially among women age 25 and under. For more information on the NCC, visit www.prevent.org/ncc.
The Guidelines are available at www.cdc.gov/std/treatment/2010/. For more information, contact 800-CDC-INFO (800-232-4636) or e-mail cdcinfo@cdc.gov.
Susan K. Maloney, MHS
Managing Senior Fellow and Senior Program Officer
Friday, 4 June 2010
Use of HPV Vaccine Still Limited
A recent analysis of surveillance data reported in the May issue of the American Journal of Preventive Medicine found that only about one third of adolescent girls ages 13-17 in a six-state sample have received more than one dose of the HPV vaccine.
Since the vaccine first received FDA approval in 2006, little research has been done to assess its use. For this analysis the researchers used data from the 2008 Behavioral Risk Factor Surveillance System and the 2000 U.S. census on 1,709 girls in Delaware, New York, Oklahoma, Pennsylvania, Texas, and West Virginia. It is not clear from the study findings why these six states were chosen. 70% of the girls in the study were white and 74% were insured.
The study also found that girls in states with higher poverty levels were less likely to be vaccinated, but those in counties with higher poverty levels were more likely to be vaccianted.
"Although seemingly contradictory, this indicates that while girls in poorer states had overall lower odds, girls living in any state experienced higher odds of vaccination if they lived in counties with higher poverty levels," said Sandi L. Pruitt, PhD, and Mario Schootman, PhD, of Washington University in St. Louis. "This may be partially explained by the limited resources of poor states," Pruitt said.
These findings show the need for interventions to increase vaccination among all eligible girls.
Christianne Johnson
Program Manager
Partnership for Prevention
Since the vaccine first received FDA approval in 2006, little research has been done to assess its use. For this analysis the researchers used data from the 2008 Behavioral Risk Factor Surveillance System and the 2000 U.S. census on 1,709 girls in Delaware, New York, Oklahoma, Pennsylvania, Texas, and West Virginia. It is not clear from the study findings why these six states were chosen. 70% of the girls in the study were white and 74% were insured.
The study also found that girls in states with higher poverty levels were less likely to be vaccinated, but those in counties with higher poverty levels were more likely to be vaccianted.
"Although seemingly contradictory, this indicates that while girls in poorer states had overall lower odds, girls living in any state experienced higher odds of vaccination if they lived in counties with higher poverty levels," said Sandi L. Pruitt, PhD, and Mario Schootman, PhD, of Washington University in St. Louis. "This may be partially explained by the limited resources of poor states," Pruitt said.
These findings show the need for interventions to increase vaccination among all eligible girls.
Christianne Johnson
Program Manager
Partnership for Prevention
Tuesday, 26 January 2010
HPV Vaccine Added to Adult Immunization Schedule
The CDC’s Advisory Committee on Immunization Practices has updated its 2010 Recommended Adult Immunization Schedule to include either of the FDA-approved human papillomavirus (HPV) vaccines for women ages 19 to 26 who have not been immunized previously against HPV. The updated recommendations appeared January 5 in the Annals of Internal Medicine.
According to the schedule, either of two recommended HPV vaccines would optimally be given to girls between the ages of 11 and 12, but women up to age 26 may benefit from “catch-up” vaccination. Both HPV vaccines are most effective when given before a woman becomes sexually active.



According to the schedule, either of two recommended HPV vaccines would optimally be given to girls between the ages of 11 and 12, but women up to age 26 may benefit from “catch-up” vaccination. Both HPV vaccines are most effective when given before a woman becomes sexually active.
Friday, 4 December 2009
Prevention a Part of Decade's Biggest Medical Breakthroughs
As the decade of the "oughts" is ending and the decades of the "teens" is about to begin, the media will no doubt be full of retrospective looks back over the past 10 years. The Daily Beast's Max Read has jumped into the fray, assembling a list of what he deemed to be the decade'[s 21 biggest medical breakthroughs. Prevention accounted for five of them. Those five are as follows:
- HPV Vaccine
- Human Vaccine against Bird Flu
- Discrediting the link between Autism and Childhood Vaccination
- Circumcision Discovered to Help Prevent HIV
- Pentacel - the 5-in-1 Childhood Vaccine
Monday, 30 November 2009
Nearly One in Four Adolescent Girls Tested Positive for STIs
A recently published study reports that nearly one in four adolescent girls were found to have had at least one sexually transmitted infection (STI), while the prevalence grew to more than one in three among girls who ackowledged being sexually experienced. "The prevalence of STIs among female adolescents is substantial, and STIs begin to be acquired soon after sexual initiation and with few sex partners," said authors of the study, which was published online in the journal "Pediatrics" on Nov. 23.
Data were analyzed from 838 females who were aged 14 to 19 and participating in the nationally representative National Health and Nutrition Examination Survey 2003–2004. After interview and examination, survey participants provided biological specimens that were tested for five STIs: Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, herpes simplex virus type 2, and human papillomavirus (HPV) (any of 23 high-risk types or type 6 or 11).
Among the conclusions :
11 to 12 years, and C trachomatis screening of sexually active female adolescents," the authors wrote.
This seems like a good place to remind readers that a new Facebook application has been launched to help educate, motivate and mobilize people to prevent the spread of Human Papillomavirus (HPV). “Fact Check: HPV” (http://www.hpvfactcheck.org/) allows users to take an interactive, educational quiz about HPV, find additional resources, and commit to take action, while even allowing concerned friends to anonymously share the application with peers.
Data were analyzed from 838 females who were aged 14 to 19 and participating in the nationally representative National Health and Nutrition Examination Survey 2003–2004. After interview and examination, survey participants provided biological specimens that were tested for five STIs: Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, herpes simplex virus type 2, and human papillomavirus (HPV) (any of 23 high-risk types or type 6 or 11).
Among the conclusions :
- Prevalence of any of the 5 STIs was 24.1% among all female adolescents and 37.7% among those deemed "sexually experienced" (gave a "yes” response to the question, “Have you ever had sex?)
- HPV was the most common STI among all female adolescents (18.3%), followed by C trachomatis infection (3.9%).
- Prevalence of any of the STIs was 25.6% among those whose age was the same or 1 year greater than their age at sexual initiation and 19.7% among those who reported only 1 lifetime sex partner.
11 to 12 years, and C trachomatis screening of sexually active female adolescents," the authors wrote.
This seems like a good place to remind readers that a new Facebook application has been launched to help educate, motivate and mobilize people to prevent the spread of Human Papillomavirus (HPV). “Fact Check: HPV” (http://www.hpvfactcheck.org/) allows users to take an interactive, educational quiz about HPV, find additional resources, and commit to take action, while even allowing concerned friends to anonymously share the application with peers.
Monday, 12 October 2009
Partnership, U-Md. Develop Novel Facebook Ap to Prevent Cervical Cancer
A new Facebook application has been launched to help educate, motivate and mobilize people to prevent the spread of Human Papillomavirus (HPV). “Fact Check: HPV” (http://www.hpvfactcheck.org/) allows users to take an interactive, educational quiz about HPV, find additional resources, and commit to take action, while even allowing concerned friends to anonymously share the application with peers. The application was developed by Partnership for Prevention and the University of Maryland’s College of Information Studies with input from the School of Public Health. The project was funded by the Fund to Prevent Cervical Cancer.
Thursday, 10 September 2009
FDA Panel OKs HPV Vaccine Gardasil for Boys
An FDA advisory committee voted to recommend approval of the vaccine Gardasil for males ages 9 to 26 to prevent genital warts. The FDA advisory committee ruled 7 to 0, with one abstaining vote, that Gardasil's clinical trial data support the vaccine's effectiveness at preventing genital warts in males ages 9 to 26. And in a 7 to 1 vote, the advisory committee ruled that the data show Gardasil to be safe for males in that age range.
Each year, about 200 out of 100,000 males are newly diagnosed with genital warts, according to background information cited by the FDA. Penile cancer and anal cancer are much rarer.
Gardasil already has FDA approval for use in females ages 9 to 26. In females, HPV can cause cervical cancer.
Thursday, 30 July 2009
Increase in Oral Sex Causing Rise in Throat Cancer
Increasing rates of HPV infection, spread through oral sex, is largely driving the rapid rise in oropharyngeal cancers, says Dr. Scott Lippman, who chairs the thoracic department at the University of Texas' M.D. Anderson Cancer Center.
Lippman says studies of oropharyngeal tumor tissue stored 20 years ago show that only around 20% are HPV positive. Today it is estimated that 60% of patients are infected with the virus.
Lippman says studies of oropharyngeal tumor tissue stored 20 years ago show that only around 20% are HPV positive. Today it is estimated that 60% of patients are infected with the virus.
Subscribe to:
Posts (Atom)